Clinical Trials Browser

Phase 2/3 × NIH × venetoclax × Clear all

NCT03984448 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Phase 2/3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse